Toll Free: 1-888-928-9744

Circulating Tumor Cells (CTC) Technologies

Published: Apr, 2015 | Pages: 384 | Publisher: RESEARCH IMPACT TECHNOLOGIES
Industry: Biotechnology | Report Format: Electronic (PDF)

This report on Circulating Tumor Cells (CTC) Technologies gives a market insight into technologies and services used for cancer detection. The market is analyzed by Cancer type into Prostate, Breast and Other; and by Function into Prognostics, Diagnostics and Therapy Management. The report serves as a guide to CTC industry, covering more than 150 companies that are engaged in CTC studies/screening, products and services. Major Contract Research Organizations, Research Institutes and Universities serving the CTC market are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. Compilation of Worldwide Patents related to CTC Technologies is also provided. A global perspective is presented along with regional analysis covering the regions of North America, Europe, and Asia-Pacific with 53 exclusive graphically represented exhibits.
 Table of Content

Circulating Tumor Cells (CTC) Technologies – Introduction	3
Circulating Tumor Cells (CTC) Technologies – Timeline	6
Biomarkers	7
CTC as a Biomarker	8
Process of Metastatic Development, CTCs and Cancer Stem Cells	8
CTCs in Blood and DTCs in Bone Marrow	9
Circulating Tumor Cells and Their Clinical Significance	9
Detection of CTCs and its Significance	10
Epithelial Mesenchymal Transition	11
Technologies for Isolation and Characterization of CTCs	11
Cell Free Nucleic Acids based CTC detection	11
CTC Detection on Physical Properties Basis	12
Antibody Capture Technology	12
Miscellaneous CTC Detection Strategies	13
CTC and Prostate Cancer	14
CTC in Breast Cancer	14
CTCs in Ovarian Cancer	14
CTC Diagnosis & Prognosis	14
CTCs as Therapy Response Marker	15
Segmentation	15
Exhibit 1. Segmentation of Global CTC Technologies Market by Cancer Type and by Function	15
CTC Technologies - Global Market Analysis	16
Exhibit 2. CTC Technologies – Global Market Estimations and Predictions (2010-2020) in US$ Billion	16
Exhibit 3. List of Major Global Companies – CTC Technologies	17
CTCs – Impact	21
Global CTC Technologies Market	22
Exhibit 4. CTC Technologies – Global Market Estimations and Predictions (2010-2020) in US$ Million for North America, Europe, Asia-Pacific and Rest of World	22
Exhibit 5. CTC Technologies – Global Market Shares (2010 & 2015) for North America, Europe, Asia-Pacific and Rest of World	23
Exhibit 6. Circulating Tumor Cells - Global Market Analysis (2010 - 2020) for Per Test Cost, Number of Tests and Cancer Incidence	24
Cancer – The Global Scene	24
Exhibit 7. List of Product/Technologies for CTC Analysis	25
North American CTC Technologies Market	27
Exhibit 8. CTC Technologies – North American Market Estimations and Predictions (2010-2020) in  US$ Million	27
United States Market Analysis	28
Exhibit 9. CTC Technologies – United States Market Estimations and Predictions (2010-2020) in US$ Million	28
Cancer Statistics	29
Exhibit 10. United States Cancer Incidence – Estimated Cases and Deaths in 2012	29
Cancer Care Cost	30
Exhibit 11. Cancer Care – National Cost (2010) by Cancer Site in US$ Billion	30
Exhibit 12. Cancer Care - Annual Costs (2010) in US$	31
Exhibit 13. CTC Technologies - Major Organizations in the North America	32
European CTC Technologies Market	33
Exhibit 14. CTC Technologies – European Market Estimations and Predictions (2010-2020) in US$ Million	33
Market Snapshots	34
Cancer Statistics	35
Exhibit 15. European Union Cancer Incidence – Reported Cases and Deaths in 2008	35
United Kingdom	36
Exhibit 16. CTC Technologies - Major Organizations in the United Kingdom	36
Germany	37
Exhibit 17. CTC Technologies - Major Organizations in Germany	37
France	38
Exhibit 18. CTC Technologies - Major Organizations in France	38
Switzerland	39
Exhibit 19. CTC Technologies - Major Organizations in Switzerland	39
Exhibit 20. CTC Technologies - Major Organizations in Rest of Europe	39
Asia-Pacific CTC Technologies Market	40
Exhibit 21. CTC Technologies – Asia-Pacific Market Estimations and Predictions (2010-2020) in US$ Million	40
Japan	41
Exhibit 22. CTC Technologies - Major Organizations in Japan	41
India	42
Exhibit 23. Cancer Incidence in India - Reported Cases and Deaths in 2008	42
Exhibit 24. CTC Technologies - Major Organizations in India	42
Rest of Asia-Pacific	43
Exhibit 25. Cancer Incidence in China - Reported Cases and Deaths in 2008	43
Exhibit 26. CTC Technologies - Major Organizations in Rest of Asia-Pacific	43
Rest of World CTC Technologies Market	44
Exhibit 27. CTC Technologies – Rest of World Market Estimations and Predictions (2010-2020) in  US$ Million	44
Israel	45
Exhibit 28. CTC Technologies - Major Organizations in Israel	45
CTC Technologies Providers – Competitor Profiles	46
Abnova Corporation (Taiwan)	46
AdnaGen AG (Germany)	47
Advanced Cell Diagnostics, Inc. (USA)	49
Affymetrix, Inc. (USA)	50
Amnis Corporation (USA)	51
ANGLE plc (UK)	52
ApoCell, Inc. (USA)	52
Applied Precision, Inc. (USA)	54
Applied Spectral Imaging, Inc. (USA)	55
Atossa Genetics, Inc. (USA)	56
AVIVA BioSciences Corporation (USA)	56
BioCEP Ltd. (Israel)	57
Biocept, Inc. (USA)	58
BioCytics, Inc. (USA)	59
BioFluidica, Inc. (USA)	60
BioView Ltd. (Israel)	62
Cancer Research UK Manchester Institute (UK)	63
Canopus Bioscience Ltd. (Canada)	64
CellTraffix, Inc. (USA)	66
Clearbridge BioMedics (Singapore)	67
Creatv MicroTech, Inc. (USA)	69
Cynvenio Biosystems, Inc. (USA)	70
CytoTrack ApS (Denmark)	71
DeNovo Sciences (USA)	73
Technology	75
DTU Fotonik (Denmark)	75
eOptra LLC (USA)	76
Epic Sciences, Inc. (USA)	77
F. Hoffmann-La Roche Ltd. (Switzerland)	77
Fluidigm Corporation (USA)	79
Fluxion Biosciences, Inc. (USA)	80
Genoptix Inc. (USA)	81
GILUPI GmbH (Germany)	82
Greiner Bio-One GmbH (Germany)	83
Ikonisys, Inc. (USA)	83
IMEC (Belgium)	84
IV Diagnostics, Inc. (USA)	85
Janssen Diagnostics BVBA (Belgium)	86
Janssen Diagnostics, LLC (USA)	86
Laboratory Dr. Pachmann (Germany)	89
Life Technologies (USA)	90
Liquid Biopsy AB (Sweden)	94
Miltenyi Biotec, Inc. (USA)	94
OncoGenex Pharmaceuticals, Inc. (USA)	95
OncoVista Innovative Therapies, Inc. (USA)	97
Progenics Pharmaceuticals, Inc. (USA)	98
R.G.C.C. International GmbH (Switzerland)	99
RareCells SAS (France)	100
RareCyte, Inc. (USA)	101
ScreenCell (France)	102
Silicon Biosystems SpA (Italy)	103
SIMFO GmbH (Germany)	104
STEMCELL Technologies, Inc. (Canada)	105
Transgenomic, Inc. (USA)	106
Vitatex, Inc. (USA)	108
Significant Market Developments	112
Fluxion Biosciences Launches IsoFlux™ NGS Assay Kits for Circulating Biomarker Detection	112
Biocept Introduces Clinical Research Services for Biomarker Detection in Circulating Tumor DNA	112
DeNovo Sciences Introduces JETTA100, Its First Commercial Instrument and Consumables	112
Thermo Fisher Acquires Life Technologies	113
Fluxion Biosciences Includes Clinical Sample Procurement to Expand IsoFlux Discovery Services	113
Epic Sciences and LabCorp Collaborate to Expedite European Clinical Sample Processing for CTC Technology	113
National Cancer Centre Singapore Partners with Clearbridge BioMedics Establishes "Singapore CTC CoRE"	114
Abnova Launches CytoQuest™ CR	114
Vitatex Licenses Proprietary CAM CTC Technology to Noble	115
ApoCell Ventures into Europe, Pools Resources with the Fraunhofer Institute for Cell Therapy and Immunology	115
ApoCell Receives Phase II Contract by Small Business Innovation Research Program	116
Advanced Cell Diagnostics Enters into Collaboration with Kindstar Global to Launch Cancer Diagnostic Tests in China	116
IMEC and SPTS Collaborate on Advanced Nanotechnology Applications in BioMEM	117
Sysmex Inostics and Bayer HealthCare Enter into Collaboration for the Development of Blood-based Companion Diagnostic Tests for Targeted Tumor Therapies	117
Sysmex Acquires Two Germany based Companies to Expand its Technology Platform Targeting Personalized Medicine and Enter New Business Fields	117
Nektar Introduces Target Specific Biomarkers for the Development of Etirinotecan Pegol	118
Clearbridge BioMedics Launches ClearCell® FX	119
GILUPI GmbH Expands Business in the Asian Markets & Attains CE-Certification for CellCollector	119
IVDIAGNOSTICS Inks Partnership Agreement with StableBody Technologies LLC	119
UCLA Further Refines 'NanoVelcro' Device to Capture Single Cancer Cell from Blood	120
Roche to Support Liquid Biopsy in Development of New CTC Detection Method	121
NCI/NIH Grants Phase II SBIR Contract to Epic Sciences for the Development of a Lung Cancer Diagnostic Blood Test	121
Veridex (now Janssen Diagnostics) Collaborates with LabCorp to Market CellSearch® CTC Test in China	121
Progenics Acquires Molecular Insight Pharmaceuticals to Expand Oncology focused Pipeline	122
NCI/NIH Grant Phase II SBIR Contract to Epic Sciences for Development of Lung Cancer Diagnostic Blood Test	122
New Category I CPT Codes and Payment Rates with Effect from 1st January for Circulating Tumor Cell Testing	123
Cynvenio Biosystems Launches LiquidBiopsy® Lab Service for Molecular Characterization of Circulating Tumor Cells for Identification of Cancer DNA Mutations	123
CELLSEARCH® 'Liquid Biopsy' Approved for Breast Cancer Patients in China	124
Abbott to Adopt Cell Imaging Software for its Automated Vysis ALK FISH Probe Test	124
Fluxion Launches IsoFlux System for Circulating Tumor Cell Analysis	125
Data Continues to Support Innovative Circulating Tumor Cell Program	125
ApoCell’s ApoStream™ CTC Isolation Technology Being Used To Explore Biomarkers as Part of Phase 3 Global Study in Metastatic Breast Cancer	126
Progenics Pharmaceuticals Initiates Phase 2 Clinical Trial of PSMA ADC in Prostate Cancer Patients	126
Affymetrix Expands QuantiGene® ViewRNA License for In-vitro Diagnostics to become Exclusive Licensee for Chromogenic Applications	126
Revised Coding and Payment Rates Likely for CTC Testing	127
Epic Sciences Enters into Partnerships with Six Pharma Cos.	127
Cynvenio Biosystems Solution for Sequencing Circulating Tumor Cells Isolated from Whole Blood	128
Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue in Advanced Prostate Cancer	128
Affymetrix Completely Acquires eBioscience Holding Company	128
Fluxion Biosciences Partners with Rubicon Genomics for CTC Analysis	129
BioView Enters into Worldwide Commercial CTC Collaboration with ScreenCell	129
Fluxion Biosciences Collaborates with Stanford University School of Medicine for Developing New Technique to Analyze CTCs	129
TeloVISION LLC Partners with Purdue Research Park to Develop Low Cost Diagnostic Products	129
IVDiagnostics Establishes a New Office in Northwest Indiana	130
COMET-1 Pivotal Trial Initiated by Exelixis for Advanced Prostate Cancer	130
Affymetrix Enters into a Global Distribution Agreement with ScreenCell over CTC Technology	131
Fluxion Biosciences Establishes New Discovery Services Division	131
Silicon Biosystems Establishes a New Laboratory in San Diego to Support Market Expansion in the US	132
OLYMPUS Europa Extends Cooperation with Applied Spectral Imaging	132
Wyss Institute Joins Hands with Children's Hospital Boston to Develop a Microfluidic Device for Culturing Rare CTCs for Diagnosis and Treatment of Cancer	132
Veridex (now Janssen Diagnostics) Joins Hands with Novartis to Promote Circulating Tumor Cells Study in Metastatic Prostate Cancer	133
Clearbridge BioMedics Obtains ISO 13485 Certification for Proprietary ClearCell™ System	133
Convention Biosystems Sign Agreement with NCI on Lung Cancer CTC Development	134
ANGLE Plc Joins Hands with Paterson Institute for Cancer Research	134
Clarient Together with Biocept Launch a New CTC Blood Test to Monitor the HER2 Status in Breast Cancer Patients	135
Transgenomic Collaborates with MD Anderson for Research on Circulating Tumor Cells using ICE COLD-PCR	135
Atossa Genetics Unveils the Latest ArgusCYTE Breast Health Test(SM) for CTC Detection	136
Transgenomic Signs a Worldwide Distribution Agreement with ScreenCell for Circulating Tumor Cell (CTC) Technology	136
Biocept Receives US Patent for its CTC (Circulating Tumor Cell) Platform	137
Biocytics Attains CAP Accreditation	137
Fluxion Biosciences Launches the New Early Access Program for its Proprietary Isoflux Rare Cell Access System	138
Clearbridge and Abnova Collaborate for the Development of an In-Vitro CTC System	138
Silicon Biosystems and Fox Chase Cancer Center Enter into Collaboration for the DEPArray™ Technology Applications	139
IV Diagnostics Gets US $244,479 in Grants under the Qualifying Therapeutic Discovery project Program (QTDP)	139
ApoCell Inks a Contract worth $2.9 Million with SAIC-F for Manufacturing and Marketing ApoStream™	139
Bioconcept Launches ‘OncoCEE-BR™’, a New CTC (Circulating Tumor Cell) Based Test for Breast Cancer	140
ApoCell Launches into the Market, a Novel Platform to Detect Circulating Cancer Cells	140
Centocor Ortho Biotech Adopts a New Corporate Identity as Janssen Biotech, Part of the Janssen Pharmaceutical Company	141
IntegenX Allies with NuGEN to Advance the Workflow of NuGEN Next-Generation Sequencing (NGS) Sample Preparation	141
Advanced Cell Diagnostics Collaborates with Definiens for the Development of Quantitative Biomarker Analysis Solutions	141
Fluidigm Launches BioMark ™ HD Real-Time PCR System	142
Veridex (now Janssen Diagnostics) and Massachusetts General Hospital Strategically Ally with Each other for State-of-the-Art CTC Technology	142
NCI (National Cancer Institute) Awards Research Grant to Advanced Cell Diagnostics, Inc. (ACD) to Further Enhance its CTCscope™ system to Detect and Analyze CTCs in the Blood	143
Phase II Trial for the Assessment of OGX-427 Treatment in Men with Advanced Prostate Cancer Initiated by OncoGenex Pharmaceuticals	144
IMEC and its Partners in Europe Initiate Project ‘MIRACLE’ for Fast and Cost-effective Cancer Diagnosis	144
AdnaGen Inks two Exclusive contracts with TATAA Molecular Diagnostics	145
Lab21 Launches the CE Marked AdnaGen’s System in the UK and Ireland	145
NCI of the United States Awards a Grant of $200K to Fluxion Biosciences to Develop Rare Cell Isolation Platform	145
AdnaGen and OncoVista Attains a US Patent for CTC Detection and Analysis Technology	146
Sparton Attains Top Position for CTC technology under Medical Innovation for 2009 at the Cleveland Clinic’s Medical Innovations Summit	146
Sysmex Europe Signs Agreement for the Distribution of AdnaGen Products Related to CTC Analysis	146
Affymetrix Takes Over Panomics	147
Advalytix Strategically Allies with M. D. Anderson Cancer Center to Study Single Circulating Tumor Cells	147
Veridex (now Janssen Diagnostics) Acquires Immunicon	148
Immunicon Receives FDA Clearance for CellSearch™ Circulating Tumor Cell Kit to Screen Metastatic Prostate Cancer Patients	148
CTC Technologies - Analysis by Cancer Type	149
Exhibit 29. CTC Technologies by Type – Global Market Estimations and Predictions (2010-2020) in US$ Million for Prostate Cancer, Breast Cancer and Other	149
Exhibit 30. CTC Technologies by Type – Global Market Shares (2010 & 2015) for Prostate Cancer, Breast Cancer and Other	150
Global Market for CTC Technologies in Prostate Cancer	150
Global Market for CTC Technologies in Breast Cancer	150
United States Market for CTC Technologies in Cancer Types	151
Exhibit 31. CTC Technologies by Type – United States Market Estimations and Predictions (2010-2020) in US$ Million for Prostate Cancer, Breast Cancer and Other	151
Exhibit 32. CTC Technologies by Type – United States Market Shares (2010 & 2015) for Prostate Cancer, Breast Cancer and Other	152
United States Market for CTC Technologies in Prostate Cancer	152
United States Market for CTC Technologies in Breast Cancer	152
Analysis by Function	153
Exhibit 33. CTC Technologies by Function – Global Market Estimations and Predictions (2010-2020) in US$ Million for Prognostics, Diagnostics and Therapy Management	153
Exhibit 34. CTC Technologies by Function – Global Market Shares (2010 & 2015) for Prognostics, Diagnostics and Therapy Management	154
Global Market for CTC Technologies in Diagnostics	154
Global Market for CTC Technologies in Prognostics	154
Global Market for CTC Technologies in Therapy Management	154
United States Market for CTC Technologies in Cancer Function	155
Exhibit 35. CTC Technologies by Function – United States Market Estimations and Predictions (2010-2020) in US$ Million for Prognostics, Diagnostics and Therapy Management	155
Exhibit 36. CTC Technologies by Function – United States Market Shares (2010 & 2015) for Prognostics, Diagnostics and Therapy Management	156
United States Market for CTC Technologies in Diagnostics	156
United States Market for CTC Technologies in Prognostics	156
United States Market for CTC Technologies in Therapy Management	156
Circulating Tumor Cells (CTC) Technologies – Market Outlook	157
Circulating Tumor Cells (CTCs) – Key Observations	159
CTC Detection	160
The Hampering Facts	160
CTC Detection – Molecular Targets	160
CTC Enumeration	160
Exhibit 37. Novel Methods for Circulating Tumor Cell Identification and Main Conclusion(s)	161
CTC Enrichment	161
Exhibit 38. CTC Enrichment Methods	162
Source: NIH	163
CTC Capture	164
CTC Isolation	164
Microfluidic Devices	164
CTCs and Cancer Stem Cells (CSCs)	165
Signaling Pathways	165
Surface Markers	165
Cancer Biomarkers	166
Tumor Marker	167
Cells as Biomarkers	168
Circulating Tumor Cells (CTCs) – Cancer Biomarkers	168
Functions of Biomarkers	169
Metronomic Chemotherapy for Cancer Treatment	169
Dispersal of Tumor Cells	170
Biology of Circulating Tumor Cells	171
Potential and Proliferative activity of Circulating Tumor Cells	171
CTCs and Epithelial Marker Genes	171
CTCs and Mesenchymal Transition	172
Stem Cell-like phenotype of CTCs	173
Changed Geno/Phenotype of CTCs when compared to Primary Tumor	173
Epithelial Mesenchymal Transition	173
Presence of CTCs in Epithelial Mesenchymal Transition and Disseminated Disease	174
Mesenchymal and Cancer Stem Cells	174
qPCR Expression Markers	175
Characterization of Protein Expression and Signaling in CTCs	175
Significance of Circulating Tumor Cells	176
Detection of CTCs and its Significance	176
CTC-Receptors	178
Major Causes of Metastasis	178
Cancer	178
Progesterone receptor Positive	179
HER-2 Positive Receptor	179
Triple Negative Type of Tumor	180
Mice models for CTC studies	181
CTC Count Prominence	181
Recent Technique on Cancer Prognosis	182
Immunofluorescent Staining Technique	182
FAST scanning	182
SERS Technology	183
CellSearch® System	183
Biochip Platforms	183
Photoacoustic Spectroscopy	184
Immunomagnetic Separation	184
Immunohistochemistry	185
CISH Technique	186
FISH Technique	186
Nanotechnology	187
Tagged- Amplicon Sequencing Technique	187
CTC Technologies	187
Techniques for Detection and Manipulation	187
Function-Based Methods	187
Nonfunction-Based Techniques	189
In Vivo CTC Manipulation Techniques	190
Challenges to In Vivo Manipulation Devices	191
Advanced CTC Detection Technologies Based on Genomics	192
CTC and Cancer Type	192
Introduction	192
Breast Cancer Therapy using Circulating Tumor Cells	193
CTC found in Early Metastasis	193
CTC Detection Methods	194
CTCs as a Biomarker in Advanced Breast Cancer	195
Detection of CTCs in Prostate & Colorectal Cancers	195
CTCs in Ovarian Cancer	196
Exhibit 39. Cancer Type and Respective Detection Methods and Markers	196
CTC Diagnosis and Prognosis	197
Circulating Tumor Cell based PSA as a Biomarkers in Prostate Cancer Prognosis	197
Exhibit 40. Clinical Studies Evaluating Circulating Tumor Cells as a Prognostic Tool	198
CTCs as Therapy Response Marker	199
CTCs in Custom-Made Medicine	200
Circulating Tumor Cells (CTC) Technologies - Research Briefs	201
Researchers Discover Cancer Cell Mechanism for Metastatic Brain Tumor Development	201
DNA Shed by Tumors have Potential for Non-Invasive Screening, Diagnosis	201
Clinical Waste May be Useful to Monitor Treatment Response in Ovarian Cancer	203
Liquid Biopsy - Enhances Cancer Diagnosis and Treatment	204
Circulating Tumor Cell Enumeration	205
Separation and Isolation of Live Tumor Cells	206
Metastasis Stem Cells Found in Blood of Breast Cancer Patient	206
Human Scabs is an Inspiration for Novel Bandage to Expedite Healing	208
Circulating Breast Tumor Cells Signature Found	208
Third Generation Gadget to Help Capturing Circulating Tumor Cells	209
Finding Circulating Tumor Cells	210
‘NanoVelcro’ Gadget to Capture Single Cancer Cells from Blood	211
Circulating Epithelial Tumor Cell (CETC) Analysis as a Diagnostic Tool for the Prognosis of Metastatic Relapse and Progression of Cancer	212
Plastin3 is a Novel Marker for Circulating Tumor Cells Undergoing the Epithelial-Mesenchymal Transition and is Associated with Colorectal Cancer Prognosis.	212
Segregating Circulating Tumor Cells using Centrifugal Forces	213
High Demands on the Cancer Diagnosis of Colon Cancer	213
Scientists Develop New Technique for the Capturing Cancer Tumor Cells from the Blood	214
Comparison between CTCs, Cancer Stem Cells and Normal Stem Cells	215
Circulating Tumor Cells as the Therapy-Related Biomarkers in Cancer Patients	215
Nanoscale Velcro-like Device Developed by Scientists to Capture and Release the Circulating Tumor Cells in Bloodstream	216
A New Nanostructure Surfaces designed to Target and Kill Circulating Tumor Cells Avoiding Leukocytes Developed by Scientists	216
A Novel CTC Isolation Platform using Selective Size Amplification (Ssa) and a Multi-Obstacle Architecture (Moa) Filter Known as Ssa-Moa Developed	217
Circulating Tumor Cells (CTCs) and Epithelial Mesenchymal Transition in Primary Breast Cancer Patients	217
Chip-Based Nanostructured Sensors Help In Precise Recognition and Categorization of Circulating Tumor Cells (CTCs) in Blood Samples taken from the Patients of Prostate Cancer	218
A New Micro Fluidic Platform using Optically-Induced-Dielectrophoretic (Odep) Force Developed for the High-Purity and Label-Free Isolation of Circulating Tumor Cells (Ctcs)	219
Highly Efficient Assay of Circulating Tumor Cells by Selective Sedimentation with a Density Gradient Medium and Microfiltration from Whole Blood	219
Breakthrough in Personalized Cancer Treatment	220
Dielectrophoresis (DEP) Technique Emerges as a New Technique for the Isolation of Circulating Tumor Cells	221
Link Between Origin of cfDNA and CTCs	221
Demystifying Circulating Tumor Cells	222
Presence of Disseminated Tumor Cells after Neoadjuvant Therapy for Locally Advanced Breast Cancer Indicates Poor Survival	223
DETECT Study initiated for In-Depth Understanding of the Prominence of Circulating Tumor Cells in Metastatic Breast Cancer Patients	223
Hepatocellular Carcinoma and CTCs – Methods used for Detection, Clinical Consequences and Future Prospects	224
CTCs in Metastatic Colorectal Cancer –A Challenge to Researchers	224
CTCs in Non-Metastatic Breast Cancer –an Upcoming Study	225
A Study on Circulating Tumor Cells in Non-Metastatic Breast Cancer	225
CTCs for the Prediction of PFS (Progression-Free Survival) and OS (Overall Survival) in Patients with Relapsed/Recurrent Ovarian Cancer	226
CTCs in Breast Cancer – Challenges of Molecular Characterization and Promise of Customized Treatment	226
University of Texas MD Anderson Cancer Center Develops a Method for Predicting CTCs in the Early Stage Breast Cancer	227
Single Cell Summary of Circulating Tumor Cells: Transcriptional Variety and Range from Breast Cancer Cell Lines	228
Secreted Vesicles Assist the Spread of Cancer in the Body	228
CTCs Very Useful for the Treatment of MBC (Metastatic Breast cancer) Except for HER2 Positive Cases	230
Biomarkers Characterized Using CTCs in Breast Cancer Patients	231
Tumor Cells are Unequal and Demonstrate Large Genetic Diversity: a Stanford Study	231
Classifying CTCs with Prostate-Cancer –Specific Micro fluidic Instrument	233
Estimation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib	233
ApoCell Introduces New Technology for CTC Capture to Identify the Lethal Liver Cancer Cells	234
Clinical Utility and Performance Validation Data Given by On-Q-ity on its Dual capture OnQChip™	235
ANGLE plc Unveils Novel PARSORTIX GEN2 SEPARATION CASSETTE, a Breakthrough Device for Cell Separation and CTC Capture	235
Lilly Conducts Study on the Flawed c-MET Receptor in Cancer Research Studies	237
Scientists Develop New Blood Tests to indentify Rare Circulating Tumor Cells	237
Epithelial Mesenchymal Transition: A Novel Methodology for CTC Detection	238
Scientists Develop a New Microdevice to Culture Isolated Rare Circulating Tumor Cells	238
Spotting of CTC through Photo Acoustic System for Early Melanoma Detection	239
Scripps Research Institute Discovers a Novel Technique to Diagnose Cancer at an Early Stage	239
Serum Marker and CTC Assessment to Evaluate the Period of progression-free survival (PFS) in Metastatic Breast Cancer	241
A Diagnostic Gene Expression Profile that Shows Presence of CTCs in Patients of Breast Cancer	241
mRNA-Seq of Individual Prostate Cancer CTCs shows Recapitulation of Gene Expression and Pathways seen in Prostate Cancer	242
Growth of Tumor-Spheres from Peripherally Circulating Tumor Cells	242
Circulating Tumor Cells and Metastasis, Clinical Efficacy in Lung Cancer Treatment	243
Changes in Tumor Cells Leads to Metastasis: a Study by the University of Granada	243
Circulating Tumor Cells Analyzed in Lung Cancer by Sensitive Detection Method	244
Impartial, Automatic Identification of a Circulating Tumor Cell Definition that Linked with Survival	244
Locating Circulating Tumor Cells for Cancer Therapy	245
Recognition and Molecular Characterization of CTCs in Breast Cancer	245
Development of Organ-specific Markers for Identifying Circulating Tumor Cells	246
Diagnostic Value of HER2 positive Circulating Tumor Cells in Metastatic Breast Cancer Patients	247
Analyzing Circulating Tumor Cells in Metastatic Breast Cancer using Artificial Neural Network Analysis	247
Use of CTCs of MBC in Patients Receiving First-Line Systemic Treatment	248
CTCs and DTCs of Primary Breast Cancer	248
Duke Cancer Institute Discover the Mechanism of the Spread of Cancer	248
Researchers Develop a New Technique based on Blood Analysis for Predicting the Effect of Drugs on Prostate Cancer	249
Strong Evidence Backs the Prognostic Value of CTCs for the Treatment of Breast Cancer	250
Analysis Conducted on a Huge Scale Reveals that Blood Test could be a “Powerful Predictor”	251
CTCs Hold Clues to an Enhanced Treatment for Breast Cancer Treatment	251
Identifying Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients who Underwent Therapy	252
‘Nano-Velcro’ Technology Adopted by UCLA Researchers to Develop Capture Circulation Cancer Cells	252
Use of Nano-partIcles Advantageous for CTC Detection	253
Cross Contamination – Free Flow Cytometry Permits Quantification of Intact CTCs	254
Categorization of MBC Patients with Unrecognized Circulating Tumor Cells	255
Latest and Upcoming Biomarkers in Breast Cancer Diagnosis and Forecast	255
Scientist Developed a Molecular Biomarker Analysis Using Circulating Tumor Cells for Cancer Detection	256
Microfluidic Devices – A New technology for the Capture of CTCs	256
CTC Based Assays for Early Detection and Prognosis of Cancer for Effective Advance in Cancer Treatment	257
Advanced CTC Analysis using Molecular Techniques Developed for Personalized Treatment of Cancer Patients	257
Assay Procedure Developed for CTC Detection in Patients Undergoing Surgery for Hepatic Metastases in Colorectal Cancer	257
CellSearch System for CTC Detection in Metastatic Breast Cancer	258
Cancer Management Clinches New Heights	258
CTCs as Genetic Signature for Detecting Lung Cancers	258
Scientists Develop New Method of Detection of CTC Using Reverse-Transcription Polymerase Chain Reaction (RT-PCR)	259
Scientists Develop Fiber-Optic Array Scanning Technology for Rare Cancer Cell Detection	260
Circulating Tumor Cells Associated with Melanoma	260
Microchip Technology to Isolate Rare CTCs	261
New In Vivo Screening Method that Scans Surface Veins for Circulating Tumor Cells	261
CTCs in Preoperative Esophageal Cancer Patients: Quantitative Assay System	262
Presence of Apoptotic and Non Apoptotic Disseminated Tumor Cells Reflect Response to Neoadjuvant Systemic Therapy (NST) in Breast Cancer	263
Significance of Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micro-metastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity	263

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $5400
Multi User - US $10600
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.